Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease

Figure 5

Response rates of pramipexole IR versus pramipexole ER. Comparison of the efficacy parameters UPDRS II + II, CGI-I and PGI at study endpoint (week 12, FAS) [13].